Nicholas Investment Partners, LP Apellis Pharmaceuticals, Inc. Transaction History

Nicholas Investment Partners, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$76.68 - $93.31 $5.94 Million - $7.23 Million	77,468 Added 22.99%	414,419 $37.8 Million
Q1 2023 May 11, 2023	BUY	$46.59 - $66.96 $4.13 Million - $5.94 Million	88,668 Added 35.71%	336,951 $22.2 Million
Q4 2022 Feb 10, 2023	BUY	$43.24 - $61.04 $2.33 Million - $3.28 Million	53,770 Added 27.64%	248,283 $12.8 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $3.09 Million - $4.81 Million	69,018 Added 55.0%	194,513 $13.3 Million
Q2 2022 Aug 10, 2022	BUY	$35.07 - $59.21 $2.23 Million - $3.76 Million	63,495 Added 102.41%	125,495 $5.68 Million
Q1 2022 May 10, 2022	BUY	$35.46 - $54.12 $2.2 Million - $3.36 Million	62,000 New	62,000 $3.15 Million

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.